
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37859307
CN-22-1733
10.2174/1570159X22666231019105328
Medicine, Neurology, Pharmacology, Neuroscience
Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study
Gao Zhiyong 1#
Xiu Meihong 2#
Liu Jiahong 1
Wu Fengchun 3*
Zhang Xiangyang 345*
1 The Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for Mental Disorder, Wenzhou, China;
2 Peking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China;
3 Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China;
4 Department of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China;
5 Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China
* Address correspondence to these authors at the Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China; Department of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China; E-mail: 13580380071@163.com; and Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China; E-mail: zhangxy9@gmail.com
# These authors contributed equally to this work.
19 10 2023
2024
22 10 17331741
20 2 2023
08 4 2023
26 4 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Background

It has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients.

Methods

The severity of the patient’s symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). A total of 237 ANFE patients were recruited and treated with risperidone (oral tablets, 4-6 mg/day twice a day) for 12 weeks. PANSS was assessed at baseline and a 12-week follow-up. Plasma TAOC levels were also assayed at baseline and week 12.

Results

Relative to nonsmokers with ANFE SZ, smokers had higher PANSS negative subscores. There was no significant difference in TAOC changes after 12 weeks of treatment with risperidone between smokers and non-smokers. However, we found greater improvement in negative symptoms in smokers compared to non-smokers. Further analysis in smokers with SZ demonstrated that improvements in negative symptoms were not associated with changes in TAOC.

Conclusion

Our study suggested that smoking affected the severity of baseline negative symptoms and further contributed to their reduction after risperidone treatment. However, improvement in negative symptoms was not dependent on the changes in TAOC.

Keywords

Schizophrenia
smoking
risperidone
total antioxidant capacity
ANFE
PANSS
==== Body
pmc1 INTRODUCTION

Schizophrenia (SZ) is a debilitating mental disorder characterized by various clinical symptoms [1-4]. The prevalence of smoking among patients with chronic SZ is estimated to be approximately about 14-88% in different countries, almost 2 times higher than the general population [5, 6]. Nicotine is one of the main psychoactive components of cigarettes, which regulates brain function through its interactive effect with the nicotinic acetylcholine receptors [7, 8]. However, the exact effect of smoking on SZ remains unclear.

Antipsychotics are the main treatment option to alleviate the clinical symptoms in patients affected by SZ [9]. Studies have shown that nicotine may be used as self-medication for clinical symptoms of SZ [10]. Nicotine may compensate for cognitive impairments of SZ by improving cognitive functioning, such as attention and visuospatial memory [11-13]. In addition, smoking can also reduce anxiety and depression symptoms because it alleviates unpleasant withdrawal symptoms [14]. A previous study speculated that anxiety reduction and sedation were the motivators for smoking in SZ [15]. However, a study by Goff et al. reported higher scores on the Brief Psychiatric Rating Scale (BPRS) and more hospitalizations among smokers [16].

Preliminary evidence suggests that excessive free radical production plays a critical role in the pathology of SZ [17, 18]. Free radicals are known to cause lipid, DNA, and protein damage in the body [19]. To combat and neutralize excess free radicals, complex antioxidants have been reported to be up-regulated in patients with SZ [20]. The body’s antioxidant defense system is dynamic and responsive to harmful oxidative stress and abnormal redox homeostasis. Antioxidants include enzymatic (catalase, glutathione peroxidase, and superoxide dismutase) and non-enzymatic (uric acid, vitamin C, glutathione, β-carotene, albumin) molecules to scavenge oxidative stress and prevent its deleterious effect once produced [21]. The imbalance between free radicals and antioxidants in favor of free radicals may contribute to oxidative stress in neurons [22]. An abnormal antioxidant defense system was found in the serum, plasma and brains of patients with SZ [4, 23, 24].

Cigarette smoke releases a complex mixture of 4000 to 7000 chemicals, including a high concentration of free radicals and other oxidants, which may increase lipid peroxidation and conversion of polyunsaturated fatty acids to hydroperoxides, endoperoxides, aldehydes and alkanes [25, 26]. Oxidative stress from smoking can be further enhanced in the lungs by the release of free radicals from macrophages [27, 28]. Cigarette smoke can cause oxidative stress not only by enhancing free radicals in smoke but also by weakening antioxidants [29]. Impaired antioxidant defense system in the blood of smokers, such as the activities of SOD, CAT, glutathione peroxidase, glutathione transferase and glutathione reductase, have been reported [30]. In addition, vitamin C levels were 40% lower in smokers than in non-smokers [31]. Other studies on smokers also revealed lower levels of uric acid in smokers than in healthy controls [32-34]. Specifically, a recent study reported that cigarette smokers had a lower average total antioxidant capacity (TAOC) than nonsmokers [35].

TAOC is a valid indicator of total antioxidant concentration in the body [36]. Studies have found abnormal TAOC in patients with SZ, which was associated with the severity of symptoms [23, 24, 37-39]. Antipsychotics have been reported to alleviate psychotic symptoms in part by modulating antioxidant defense systems [40]. There is indeed a growing body of evidence that antipsychotics can regulate TAOC [41]. Risperidone is an atypical antipsychotic for the treatment of patients with SZ [42], which is usually administered as oral tablets (4-6 mg/day) twice a day. We chose risperidone as an antipsychotic because it does not exhibit significant α7 nicotinic acetylcholine receptor agonism or 5-HT3 receptor antagonism [43]. Also, smoking has been reported to have a possible effect on the pharmacokinetics and metabolism of antipsychotics [44]. Cigarette smoking induces CYP1A2 activity, leading to a decrease in risperidone plasma levels [45]. However, to date, no studies have investigated the impact of smoking on TAOC and the pathophysiology of SZ after treatment with risperidone. We hypothesize that smoking affects the therapeutic response to risperidone, which was dependent on TAOC in patients with ANFE SZ. Therefore, we aimed to explore (1) whether TAOC was different between smokers and nonsmokers; (2) whether smoking had an impact on clinical symptoms after risperidone monotherapy for 12 weeks; and (3) whether improvement in symptoms was dependent on the changes in TAOC.

2 MATERIALS AND METHODS

2.1 Participants

Two hundred and thirty-seven ANFE patients with SZ were recruited from Beijing hui-long-guan Hospital and Henan Zhu-Ma-Dian Hospital. All patients met the DSM-IV diagnosis of SZ based on the Structured Clinical Interview I for DSM-IV (SCID-I) criteria. Patients with any other major Axis I disorder were excluded from this study. Patients were first-episode and drug-naïve, were between 16 and 45 years of age, and had a cumulative use of antipsychotic drugs < 14 days. The duration of the illness was no more than 5 years. One hundred and twenty-five unrelated, age- and sex-matched healthy controls (HC) participated in the present study. We also excluded HCs with psychiatric disorders through the SCID interviews.

In addition, we obtained a complete set of medical history, physical examinations, and laboratory tests from patients and HCs. Participants were excluded if they had major medical comorbidities (i.e., infection, diabetes and hypertension), cerebrovascular diseases, took over-the-counter antioxidants or were pregnant. HC subjects were also assessed for personal history of psychiatric disorders based on the SCID. If HCs had a first-degree relative diagnosed with a mental disorder, they were excluded.

The present study was approved by the Ethical Committee of Beijing Hui-long-guan Hospital in accordance with the Declaration of Helsinki. All subjects provided written informed consent for participation in this study.

ANFE patients with SZ were treated with oral risperidone (4-6 mg/day) for 12 weeks. Risperidone was administered as oral tablets twice a day. The risperidone treatment started with 1 mg/day, with increments of 1 mg every 3 days according to the reaction and tolerance of patients. Finally, the dose of risperidone usually reached 4-6 mg/day over 2 weeks.

2.2 Assessments and Outcomes

Six psychiatrists assessed the clinical symptoms using the Positive and Negative Syndrome Scale (PANSS). After a training course on how to use this scale, an inter-observer correlation coefficient greater than 0.8 for PANSS total score was maintained across repeated evaluations. Clinical symptoms were assessed at baseline and the 12-week endpoint.

A smoker is defined as someone who smokes at least one cigarette a day and has been smoking for more than one year. Nonsmokers are defined as people who have never smoked or have smoked less than 100 cigarettes in their lifetime [46].

2.3 Determination of TAOC Activity

Blood samples were obtained from all participants after fasting for 12 hours and stored at -80°C until TAOC was assayed. TAOC was determined by two experienced technicians through the kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), who were blinded to the participant’s status [47]. In brief, TAOC was measured by the FRAP method, expressed as reductants from Fe3+ to Fe2+, which were chelated by 2,4,6-tri-pyridyl-s-triazine (TPTZ) to form a Fe2+-TPTZ complex. The complex was absorbed in 593 nm and detected by a Multiskan microplate reader.

2.4 Statistical Analysis

Demographic characteristics between smokers and nonsmokers with SZ were compared by X2 test and independent sample t-test. Analysis of covariance (ANCOVA) was performed to examine whether there was a significant difference in TAOC between HCs and patients at baseline. The covariables included sex, age and onset age, which have previously been shown to be associated with oxidative stress. We used the G*Power 3.1.9.2 program to run a power calculation and determine the sample size.

Analyses of the main outcomes were conducted by intention-to-treat analysis (ITT), including all patients who provided baseline and second-month assessments. Clinical symptoms and TAOC were compared between baseline and follow-up using paired t-tests. To investigate the impact of smoking status on the main outcomes and TAOC, a repeated-measures ANCOVA (Rm ANCOVA) was conducted with smoking status as a dependent variable adjusting for the age, sex and onset age. Pearson’s correlations or Spearman’s correlations were used to examine the correlation between the changes in TAOC and PANSS or between baseline TAOC and changes in PANSS in smokers and non-smokers, respectively. Changes in PANSS and biomarkers between follow-up and baseline were calculated by subtracting the baseline values from the follow-up values. Further linear regression was performed to determine whether the changes in TAOC were associated with improvements in clinical symptoms after adjusting for covariates in smokers and nonsmokers, respectively.

SPSS (Statistical Package for the Social Sciences) software was performed in all statistical analyses. Statistical significance was taken as p < 0.05.

3 RESULTS

3.1 Demographic and Clinical Data at Baseline between Smokers and Non-smokers with SZ

There were 67 smokers and 170 non-smokers in the patient group and 45 smokers and 80 non-smokers in the HC group. The demographic and clinical characteristics between smokers and non-smokers in patients are shown in Table 1. There were significant differences in age, age of onset, and negative symptoms between smokers and non-smokers with SZ (all p < 0.05) (Table 1). Among patients, smokers were older, had a higher age of onset and had more severe negative symptoms than nonsmokers.

As reported in our previous study, baseline TAOC was significantly higher in ANFE patients than HCs [48]. Baseline TAOC was not associated with age, onset age, and years of education (all p > 0.05). There was no significant difference in TAOC between smokers and non-smokers with SZ (216.5 ± 68.3 vs. 225.6 ± 68.4, F = 0.9, p = 0.36). Moreover, we found no difference in TAOC between smokers and non-smokers in the whole subjects (p > 0.05).

3.2 Symptoms Improvements and TAOC after Treatment between two Groups

Rm ANCOVA analysis found that after treatment for 3 months, PANSS total score and all its subscores were significantly decreased after controlling for age, sex, and onset age (p < 0.05). There were significant interaction effects of time and smoke on negative symptoms (F = 11.9, p = 0.001) and PANSS total score (F = 4.4, p = 0.036) (Table 2 and Fig. 1), after controlling for age, sex and onset age. In smokers, negative symptoms and PANSS total score were significantly reduced after treatment (N: 20.5 ± 7.7 vs. 14.1 ± 6.1, changes: 6.4 ± 7.6, t = 6.5, p <0.001; Total: 79.6 ± 20.2 vs. 50.6 ± 13.4, changes: 29.1 ± 20.2, t = 11.0, p <0.001). Moreover, significant improvements in negative symptoms and total score were found in non-smokers (N: 18.0 ± 6.6 vs. 14.1 ± 5.5, changes: 4.0 ± 5.5, t = 8.6, p <0.001; Total: 75.2 ± 17.1 vs. 50.7 ± 12.7, changes: 24.4 ± 17.6, t = 16.7, p <0.001) (Fig. 1). Further analysis found that smokers showed greater improvement in negative symptoms and PANSS total score than non-smokers after controlling for covariates (all p < 0.05). However, there was no significant interaction effect of time and smoke and the main effect of smoke on positive symptoms, general psychopathology or TAOC (all p > 0.05) (Table 2 and Fig. 2).

3.3 Association between Smoking, Baseline TAOC, Changes in TAOC and Improvements in Clinical Symptoms

Among smokers and non-smokers with SZ, baseline TAOC was negatively correlated with the improvements in positive symptoms, general psychopathology, and total PANSS score (all p < 0.05) (Table 3). In addition, regression analysis supported the association of baseline TAOC with the improvements in these clinical symptoms among both groups after controlling for age, sex and onset age (Table 3). Smoke did not affect the association between baseline TAOC and symptom improvement in patients with SCZ.

We further analyzed whether changes in TAOC were associated with improvements in clinical symptoms among smokers and non-smokers with SZ. The results showed that smoking showed no impact on the association between the increase in TAOC and the improvement in PANSS total score or its subscores (all p > 0.05).

4 DISCUSSION

This is the first and largest study to evaluate the impact of smoking on TAOC and symptoms in patients with SZ after 12 weeks of risperidone monotherapy. This study had several findings, which are as follows:

There was no difference in plasma TAOC between smokers and non-smokers with SZ.

After 12 weeks of treatment, TAOC increased significantly in both smokers and non-smokers, and baseline TAOC was associated with a reduction in clinical symptoms after risperidone treatment.

Smokers showed greater improvement in negative symptoms and total score than non-smokers.

Cigarette smoke is highly prevalent in SZ, but its effect on symptoms and relationship to oxidative stress in SZ is not known [49]. Our finding of no significant difference in baseline TAOC between smokers and non-smokers suggests that smoking had no impact on plasma TAOC concentrations in the early stage of SZ. Our study was consistent with previous studies on SZ [50, 51]. For example, Ballesteros et al. found no significant effect of smoking and medications on the concentrations of glutathione (GSH) [51]. However, other studies have reported conflicting findings. Gould et al. found that tobacco smoking causes an adaptive antioxidant response and increases systemic glutathione production [52]. Zhang et al. reported an increase in the antioxidant enzymes in patients with SZ who smoked [53]. The inconsistency may be due to the differences in antioxidant molecules, sample type, and disease progression.

In addition, we failed to find a significant difference in the increase of TAOC between smokers and non-smokers after treatment with risperidone for 3 months. The increase in TAOC indicated that antipsychotics might upregulate antioxidants early in treatment, independent of smoking. To the best of our knowledge, this is the first study to directly assess the association between smoking and changes in TAOC following antipsychotic treatment in ANFE patients with SZ. The finding of increased TAOC suggested that the elaborate redox system in favor of antioxidants exists in the early stage of treatment in SZ. As a compensatory mechanism, the elevated TAOC was caused by excess free radicals. However, this elevation was not influenced by the smoking status of patients. Therefore, future studies are warranted to evaluate the effect of antipsychotic drugs on TAOC and other antioxidant molecules in SZ.

We further found that smoking affected the improvement of negative symptoms during the treatment with risperidone in patients and that smokers showed a greater improvement in negative symptoms than non-smokers. Our findings were in line with previous clinical and animal studies [54, 55]. Smoking has indeed been reported to be used as self-medication because of its direct pharmacotherapeutic effects, such as sedative, stimulant and sensorimotor manipulation properties [56]. Increased activity of the midbrain dopaminergic and reward systems has been reported after systemic administration of nicotine in rats [54], which may be a potential mechanism for reducing negative symptoms in SZ. Smoking helps to confront problems, gives pleasure, and alleviates the symptoms [57]. Nicotine plays a critical role in psychiatric disorders, probably because it increases the activity of the liver cytochrome P450 enzyme and increases the metabolisms of antipsychotic drugs. In addition, smoking reduces dopamine degradation, enhances dopaminergic activity, and activates reward-related neural regions in the frontal-subcortical circuitry (mesocortical dopamine pathways). Thus, smoking increases dopamine levels by causing dopamine release and inhibiting its degradation, which then further reduces the negative symptoms in patients with SZ [58-60]. Therefore, in smokers, risperidone is more effective than in non-smokers for negative symptoms. Although smoking did not alter TAOC, it is unclear whether smoking alters other antioxidant molecules. In addition, we measured TAOC only in the blood rather than in CNS or CSF. Therefore, this study is preliminary, and the association of TAOC with smoking and clinical symptoms in SZ merits further investigation.

Notably, smokers with SZ showed greater negative symptoms than non-smokers at baseline. We do not know the exact reason for this finding. However, it has been reported that chronic nicotine exposure desensitizes nicotinic receptors and reduces the cholinergic activity in the prefrontal cortex of patients with SZ, which may adversely affect the negative symptoms [61]. Indeed, cigarette smoke is a complex process involving psychopathological, biochemical and neuropharmacological domains in patients with SZ [62]. Previous findings in the literature were inconsistent. There were few clinical data suggesting that nicotine helps to reduce negative symptoms in patients suffering from SZ [63]. Dixon et al. (2007) reported a decrease in negative symptoms and an increase in positive symptoms in patients affected by SZ with higher severity of smoking [64]. On the contrary, Barnes et al. showed no significant difference in clinical symptoms between smoking and non-smoking patients [65]. In particular, Krishnadas et al. found that patients with severe nicotine dependence had higher scores on the positive PANSS subscale, while patients with mild to moderate dependence had higher scores on the negative subscale [66]. Therefore, further studies on the role of smoking and nicotine in the clinical symptoms of SZ are warranted.

The strength of our study included the relatively large sample size, a prospective design, and the use of drug naïve first-episode patients with SZ. However, several limitations should also be noted in this study. First, only TAOC levels were measured in this study. Many enzymatic and non-enzymatic antioxidants were not determined, which need to be measured in future studies. Second, some other risk factors should also be considered in future research, such as dietary style, lifestyle, and physical exercise. Third, the number of cigarettes smoked and the severity of nicotine dependence were missed; therefore, the associations between the severity of nicotine and improvements in clinical symptoms and TAOC levels were not investigated. Fourth, another limitation was a lack of data on BMI and insulin resistance, which have been reported to have a significant role in response to treatment, cognitive dysfunction, and complex inflammatory and oxidant processes in first-episode patients with SZ. Fifth, only the effect of risperidone was examined in this study. Future studies should investigate whether other antipsychotics have similar findings.

CONCLUSION

In summary, this study found a significant effect of smoking on the improvement of negative symptoms after treatment with risperidone in patients with ANFE SZ. However, smoking showed no impact on TAOC or the changes after treatment. Therefore, in clinical practice, there is no need to pay particular attention to smoking cessation in patients with SZ, considering that smoking shows a non-significant effect on total antioxidant status but further improves negative symptoms. However, it is only a preliminary study and needs replication in other conventional antipsychotics. Future studies are also warranted to investigate the additive effect of smoking on the clinical symptoms and redox system in the early treatment of SZ.

ACKNOWLEDGEMENTS

The authors would like to thank Dong Wang for all of his hard work and significant contributions to the study.

AUTHORS’ CONTRIBUTIONS

ZG, XZ, and FW contributed to conceptualization (creating ideas and overarching research goals) and methodology. ZG, MX, JL, and FW gathered data, MX analyzed data, XZ and ZG drafted the manuscript. All authors read and approved the final manuscript.

LIST OF ABBREVIATIONS

ANFE Antipsychotic-naïve First-episode

BPRS Brief Psychiatric Rating Scale

HC Healthy Controls

PANSS Positive and Negative Syndrome Scale

SZ Schizophrenia

TAOC Total Antioxidants Capacity

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Institutional Review Board of Beijing Huilongguan Hospital, China.

HUMAN AND ANIMAL RIGHTS

This study was conducted according to the guidelines of the Declaration of Helsinki and approved by Ethics Committee.

CONSENT FOR PUBLICATION

Informed, written consent was obtained from all subjects involved in the study.

STANDARDS OF REPORTING

STROBE guidelines and methodology were followed.

AVAILABILITY OF DATA AND MATERIALS

The datasets generated during and/or analyzed during this study are available from the corresponding author upon reasonable request.

FUNDING

This study was supported by grants from the Science and Technology Program of Guangzhou (202206060005, 202201010093, SL2022A03J01489), and the Guangdong Basic and Applied Basic Research Foundation Outstanding Youth Project (2021B1515020064), Medical Science and Technology Research Foundation of Guangdong (A2023224), the Health Science and Technology Program of Guangzhou (20231A010036), Scientific research project of traditional Chinese medicine of Guangdong (20211306).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) There were significant interaction effects of time and smoke on negative symptoms in patients with schizophrenia after treatment with risperidone (F = 11.9, p = 0.001) and PANSS total score (F = 4.4, p = 0.036).

Fig. (2) There was no significant interaction effects of time and smoke on TAOC levels in patients with schizophrenia after treatment with risperidone (p > 0.05).

Table 1 Demographic characteristics and clinical data in antipsychotics-naive first episode (ANFE) patients with schizophrenia (SZ) and healthy controls.

Variable	SZ	p-value	HC	p-value	
Non-smokers
(n = 170)	Smokers
(n = 67)	Non-smokers
(n = 80)	Smokers
(n = 45)	
Sex (male/female)	70/100	58/9	< 0.001	37/43	40/5	< 0.001	
Age (years)	26.7 ± 9.2	30.6 ± 8.6	0.03	26.5 ± 7.4	29.6 ± 8.6	0.03	
Education (years)	9.3 ± 3.9	8.2 ± 3.8	0.05	10.9 ± 3.0	9.3 ± 3.0	0.007	
Age of onset (years)	25.4 ± 9.1	28.6 ± 9.0	0.016	-	-	-	
PANSS score	-	-	-	-	
   P
   N
   G
Total score	21.6 ± 6.1
18.2 ± 6.5
35.0 ± 9.3
74.6 ± 16.2	22.3 ± 6.9
20.6 ± 7.6
36.8 ± 10.1
79.5 ± 19.5	0.46
0.016
0.19
0.05	-	-	-	
Note: PANSS the positive and negative syndrome scale; P positive symptoms; N negative symptoms; G general psychopathology.

Table 2 Comparisons of clinical symptoms and TAOC levels before and 3 months after risperidone monotherapy using Rm ANCOVA.

-	Baseline	12-week follow-up	Effecta	
Non-smokers
n = 142b	Smokers
n = 59b	Non-smokers
n = 142b	Smokers
n = 59b	Time
F(p)a	Smoke
F(p)a	Interaction
F(p)a	
P	22.0 ± 6.3	22.4 ± 7.1	11.8 ± 4.4	11.6 ± 4.3	10.4(0.001)	0.2(0.70)	1.2(0.28)	
N	18.0 ± 6.6	20.5 ± 7.7	14.1 ± 5.5	14.1 ± 6.1	5.8(0.017)	1.6(0.27)	11.9(0.001)	
G	35.5 ± 9.8	36.9 ± 10.5	24.8 ± 5.7	24.8 ± 6.7	6.2(0.014)	0.1(0.71)	1.5(0.22)	
Total score	75.2 ± 17.1	79.6 ± 20.0	50.7 ± 12.7	50.6 ± 13.4	10.7(0.001)	0.7(0.40)	4.4(0.036)	
TAOC	219.0 ± 67.3	208.4 ± 64.7	273.6 ± 103.5	248.4 ± 108.3	41.5(< 0.001)	1.0(0.32)	2.5(0.12)	
Note: aThe p values were adjusted for sex, age, and onset age, bThese numbers were the sample size after dropout.

P positive symptoms; N negative symptoms; G general psychopathology; TAOC total antioxidants capacity.

Table 3 Correlation and regression analysis of the associations between baseline TAOC levels.

	Pearson Correlation Analysis	Regression Analysis	
Smokers	
	r	p	β	t	p	
P	-0.44	0.001	-0.39	-3.13	0.003	
N	-0.15	0.25	-0.12	-0.94	0.35	
G	-0.36	0.006	-0.31	-2.35	0.02	
Total score	-0.39	0.002	-0.34	-2.67	0.01	
Non-smokers	
	r	p	β	t	p	
P	-0.27	0.001	-0.28	-3.30	0.001	
N	-0.05	0.57	-0.23	-0.27	0.79	
G	-0.17	0.04	-0.16	-1.89	0.06	
Total score	-0.20	0.014	-0.19	-2.25	0.026	
Note: P positive symptoms; N negative symptoms; G general psychopathology.
==== Refs
REFERENCES

1 Fang X. Chen Y. Wang Y. Ren J. Zhang C. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog. Neuropsychopharmacol. Biol. Psychiatry 2019 95 109673 10.1016/j.pnpbp.2019.109673 31247244
2 Fang X. Chen Y. Wang Y. Zhang C. Identification of risk factors for suicidal ideation in patients with schizophrenia. Psychiatry Res. 2019 271 195 199 10.1016/j.psychres.2018.11.051 30500709
3 Xiu M.H. Lang X. Chen D.C. Cao B. Kosten T.R. Cho R.Y. Shi H. Wei C.W. Wu A.S. Zhang X.Y. Cognitive deficits and clinical symptoms with hippocampal subfields in first-episode and never-treated patients with Schizophrenia. Cereb. Cortex 2021 31 1 89 96 10.1093/cercor/bhaa208 32901269
4 Xiu M.H. Li Z. Chen D.C. Chen S. Curbo M.E. Wu H.E. Tong Y.S. Tan S.P. Zhang X.Y. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with Schizophrenia. Schizophr. Bull. 2020 46 6 1498 1510 10.1093/schbul/sbaa062 32390043
5 Šagud M. Vuksan-Ćusa B. Jakšić N. Mihaljević-Peleš A. Rojnić K.M. Pivac N. Smoking in Schizophrenia: An updated review. Psychiatr. Danub. 2018 30 Suppl. 4 216 223 29864763
6 Ding J.B. Hu K. Cigarette smoking and schizophrenia: Etiology, clinical, pharmacological, and treatment implications. Schizophr. Res. Treatment 2021 2021 1 8 10.1155/2021/7698030 34938579
7 Changeux J.P. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat. Rev. Neurosci. 2010 11 6 389 401 10.1038/nrn2849 20485364
8 Dome P. Lazary J. Kalapos M.P. Rihmer Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2010 34 3 295 342 10.1016/j.neubiorev.2009.07.013 19665479
9 Zhu M.H. Liu Z.J. Hu Q.Y. Yang J.Y. Jin Y. Zhu N. Huang Y. Shi D.H. Liu M.J. Tan H.Y. Zhao L. Lv Q.Y. Yi Z.H. Wu F.C. Li Z.Z. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: A 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res. 2022 9 1 59 10.1186/s40779-022-00420-0 36253804
10 Addington J. el-Guebaly N. Campbell W. Hodgins D.C. Addington D. Smoking cessation treatment for patients with schizophrenia. Am. J. Psychiatry 1998 155 7 974 975 10.1176/ajp.155.7.974 9659869
11 Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int. J. Neurosci. 1993 70 3-4 193 197 10.3109/00207459309000574 8063538
12 Taiminen T.J. Salokangas R.K.R. Saarijärvi S. Niemi H. Lehto H. Ahola V. Syvälahti E. Smoking and cognitive deficits in schizophrenia: A pilot study. Addict. Behav. 1998 23 2 263 266 10.1016/S0306-4603(97)00028-2 9573430
13 Dépatie L. O’Driscoll G.A. Holahan A.L. Atkinson V. Thavundayil J.X. Kin N.N. Lal S. Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002 27 6 1056 1070 10.1016/S0893-133X(02)00372-X 12464463
14 Williams J.M. Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict. Behav. 2004 29 6 1067 1083 10.1016/j.addbeh.2004.03.009 15236808
15 Barr A.M. Procyshyn R.M. Hui P. Johnson J.L. Honer W.G. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr. Res. 2008 100 1-3 252 260 10.1016/j.schres.2007.11.027 18178062
16 Goff D.C. Henderson D.C. Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am. J. Psychiatry 1992 149 9 1189 1194 10.1176/ajp.149.9.1189 1503131
17 Cecerska-Heryć E. Polikowska A. Serwin N. Roszak M. Grygorcewicz B. Heryć R. Michalczyk A. Dołęgowska B. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem. Int. 2022 153 105269 10.1016/j.neuint.2021.105269 34971747
18 Murray A.J. Rogers J.C. Katshu M.Z.U.H. Liddle P.F. Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry 2021 12 703452 10.3389/fpsyt.2021.703452 34366935
19 Kim K.B. Lee B.M. Oxidative stress to DNA, protein, and antioxidant enzymes (superoxide dismutase and catalase) in rats treated with benzo(a)pyrene. Cancer Lett. 1997 113 1-2 205 212 10.1016/S0304-3835(97)04610-7 9065823
20 Yao J.K. Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Signal. 2011 15 7 2011 2035 10.1089/ars.2010.3603 21126177
21 Wu J.Q. Kosten T.R. Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013 46 200 206 10.1016/j.pnpbp.2013.02.015 23470289
22 MacNEE W.; Rahman, I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999 160 5 Pt 2 S58 S65 10.1164/ajrccm.160.supplement_1.15 10556172
23 Liu H. Yu R. Gao Y. Li X. Guan X. Thomas K. Xiu M. Zhang X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr. Neuropharmacol. 2022 20 9 1774 1782 34544343
24 Li X.R. Xiu M.H. Guan X.N. Wang Y.C. Wang J. Leung E. Zhang X.Y. Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics 2021 18 2 1316 1324 10.1007/s13311-021-01036-3 33791970
25 Morrow J.D. Frei B. Longmire A.W. Gaziano J.M. Lynch S.M. Shyr Y. Strauss W.E. Oates J.A. Roberts L.J. II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 1995 332 18 1198 1203 10.1056/NEJM199505043321804 7700313
26 Montuschi P. Collins J. Ciabattoni G. Lazzeri N. Corradi M. Kharitonov S.A. Barnes P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000 162 3 1175 1177 10.1164/ajrccm.162.3.2001063 10988150
27 MacNee W. Oxidants/Antioxidants and COPD. Chest 2000 117 5 Suppl. 1 303S 317S 10.1378/chest.117.5_suppl_1.303S-a 10843965
28 Kirkham P. Rahman I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther. 2006 111 2 476 494 10.1016/j.pharmthera.2005.10.015 16458359
29 James R.W. Leviev I. Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000 101 19 2252 2257 10.1161/01.CIR.101.19.2252 10811591
30 Ahmadi-Motamayel F. Falsafi P. Goodarzi M.T. Poorolajal J. Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: A retrospective cohort study. J. Oral Pathol. Med. 2017 46 5 377 380 10.1111/jop.12495 27800633
31 Northrop-Clewes C.A. Thurnham D.I. Monitoring micronutrients in cigarette smokers. Clin. Chim. Acta 2007 377 1-2 14 38 10.1016/j.cca.2006.08.028 17045981
32 Garg N. Singh R. Dixit J. Jain A. Tewari V. Levels of lipid peroxides and antioxidants in smokers and nonsmokers. J. Periodontal Res. 2006 41 5 405 410 10.1111/j.1600-0765.2006.00889.x 16953817
33 Kanehira T. Shibata K. Kashiwazaki H. Inoue N. Morita M. Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology 2006 23 1 38 42 10.1111/j.1741-2358.2006.00077.x 16433640
34 Abdolsamadi H.R. Goodarzi M.T. Mortazavi H. Robati M. Ahmadi-Motemaye F. Comparison of salivary antioxidants in healthy smoking and non-smoking men. Chang Gung Med. J. 2011 34 6 607 611 22196063
35 Ahmadi-Motamayel F. Falsafi P. Abolsamadi H. Goodarzi M.T. Poorolajal J. Evaluation of salivary antioxidants and oxidative stress markers in male smokers. Comb. Chem. High Throughput Screen. 2019 22 7 496 501 10.2174/1386207322666190806123616 31385764
36 Şenyurt, M.; Aybek, H.; Herken, H.; Kaptanoglu, B.; Korkmaz, A Evaluation of oxidative status in patients treated with electroconvulsive therapy. Clin. Psychopharmacol. Neurosci. 2017 15 1 40 46 10.9758/cpn.2017.15.1.40 28138109
37 Liu H. Liu H. Jiang S. Su L. Lu Y. Chen Z. Li X. Li X. Wang X. Xiu M. Zhang X. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: A prospective longitudinal study. Curr. Neuropharmacol. 2022 20 9 1793 1803 10.2174/1570159X19666211111123918 34766896
38 Virit O. Altindag A. Yumru M. Dalkilic A. Savas H.A. Selek S. Erel O. Herken H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009 60 2 87 93 10.1159/000239684 19776652
39 Li X.F. Zheng Y.L. Xiu M.H. Chen D.C. Kosten T.R. Zhang X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011 35 4 1064 1067 10.1016/j.pnpbp.2011.03.001 21392552
40 Möller H.J. Czobor P. Pharmacological treatment of negative symptoms in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2015 265 7 567 578 10.1007/s00406-015-0596-y 25895634
41 Al-chalabi B.M. Thanoon I.A.J. Ahmed F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 2009 59 1 8 11 10.1159/000202823 19221442
42 Aringhieri S. Carli M. Kolachalam S. Verdesca V. Cini E. Rossi M. McCormick P.J. Corsini G.U. Maggio R. Scarselli M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther. 2018 192 20 41 10.1016/j.pharmthera.2018.06.012 29953902
43 Shiina A. Shirayama Y. Niitsu T. Hashimoto T. Yoshida T. Hasegawa T. Haraguchi T. Kanahara N. Shiraishi T. Fujisaki M. Fukami G. Nakazato M. Iyo M. Hashimoto K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry 2010 9 1 27 10.1186/1744-859X-9-27 20573264
44 Haslemo T. Eikeseth P.H. Tanum L. Molden E. Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur. J. Clin. Pharmacol. 2006 62 12 1049 1053 10.1007/s00228-006-0209-9 17089108
45 Schoretsanitis G. Haen E. Stegmann B. Hiemke C. Gründer G. Paulzen M. Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophr. Res. 2017 185 51 57 10.1016/j.schres.2016.12.016 27993531
46 Zhang X.Y. Chen D.C. Xiu M.H. Haile C.N. Sun H. Lu L. Kosten T.A. Kosten T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: A case-control study. PLoS One 2012 7 5 e36563 10.1371/journal.pone.0036563 22570726
47 Koga M. Serritella A.V. Sawa A. Sedlak T.W. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr. Res. 2016 176 1 52 71 10.1016/j.schres.2015.06.022 26589391
48 Wang K. Xiu M. Su X. Wu F. Zhang X. Association between changes in total antioxidant levels and clinical symptom improvement in patients with antipsychotic-naïve first-episode schizophrenia after 3 months of risperidone monotherapy. Antioxidants (Basel) 2022 11 4 646 10.3390/antiox11040646 35453331
49 Cooper J. Mancuso S.G. Borland R. Slade T. Galletly C. Castle D. Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Aust. N. Z. J. Psychiatry 2012 46 9 851 863 10.1177/0004867412449876 22645396
50 Ischemia-modified albumin: A unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology 2019 29 2 7
51 Ballesteros A. Jiang P. Summerfelt A. Du X. Chiappelli J. O’Donnell P. Kochunov P. Hong L.E. No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr. Res. 2013 146 1-3 184 189 10.1016/j.schres.2013.02.001 23466187
52 Gould N.S. Min E. Gauthier S. Martin R.J. Day B.J. Lung glutathione adaptive responses to cigarette smoke exposure. Respir. Res. 2011 12 1 133 10.1186/1465-9921-12-133 21982222
53 Zhang X.Y. Tan Y.L. Zhou D.F. Haile C.N. Wu G.Y. Cao L.Y. Kosten T.A.R. Kosten T. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 2007 32 9 2020 2024 10.1038/sj.npp.1301317 17228336
54 Grenhoff J. Aston-Jones G. Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 1986 128 3 351 358 10.1111/j.1748-1716.1986.tb07988.x 3788613
55 Hall R.G. Duhamel M. McClanahan R. Miles G. Nason C. Rosen S. Schiller P. Tao-Yonenaga L. Hall S.M. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J. Nerv. Ment. Dis. 1995 183 7 468 471 10.1097/00005053-199507000-00008 7623020
56 Al-Halabí S. Fernández-Artamendi S. Díaz-Mesa E.M. García-Álvarez L. Flórez G. Martínez-Santamaría E. Arrojo M. Saiz P.A. García-Portilla M.P. Bobes J. Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study. Adicciones 2016 29 1 6 12 27391843
57 Oliveira R.M. Siqueira Júnior A.C. Santos J.L.F. Furegato A.R.F. Nicotine dependence in the mental disorders, relationship with clinical indicators, and the meaning for the user. Rev. Lat. Am. Enfermagem 2014 22 4 685 692 10.1590/0104-1169.3549.2468 25296154
58 Drew A.E. Derbez A.E. Werling L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 2000 38 1 10 16 10.1002/1098-2396(200010)38:1<10:AID-SYN2>3.0.CO;2-T 10941136
59 Glassman A.H. Cigarette smoking: Implications for psychiatric illness. Am. J. Psychiatry 1993 150 4 546 553 10.1176/ajp.150.4.546 8465868
60 Nomikos G.G. Schilström B. Hildebrand B.E. Panagis G. Grenhoff J. Svensson T.H. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res. 2000 113 1-2 97 103 10.1016/S0166-4328(00)00204-7 10942036
61 Patkar A.A. Gopalakrishnan R. Lundy A. Leone F.T. Certa K.M. Weinstein S.P. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J. Nerv. Ment. Dis. 2002 190 9 604 610 10.1097/00005053-200209000-00005 12357094
62 Lohr J. Flynn K. Smoking and schizophrenia. Schizophr. Res. 1992 8 2 93 102 10.1016/0920-9964(92)90024-Y 1360812
63 Aguilar M.C. Gurpegui M. Diaz F.J. De Leon J. Nicotine dependence and symptoms in schizophrenia. Br. J. Psychiatry 2005 186 3 215 221 10.1192/bjp.186.3.215 15738502
64 Dixon L. Medoff D.R. Wohlheiter K. Dixon L. Medoff D.R. Wohlheiter K. DiClemente C. Goldberg R. Kreyenbuhl J. Adams C. Lucksted A. Davin C. Correlates of severity of smoking among persons with severe mental illness. Am. J. Addict. 2007 16 2 101 110 10.1080/10550490601184415 17453611
65 Barnes M. Lawford B.R. Burton S.C. Heslop K.R. Noble E.P. Hausdorf K. Young R.M. Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust. N. Z. J. Psychiatry 2006 40 6-7 575 580 10.1080/j.1440-1614.2006.01841.x 16756583
66 Krishnadas R. Jauhar S. Telfer S. Shivashankar S. McCreadie R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry 2012 201 4 306 312 10.1192/bjp.bp.111.107953 22878134
